D.N.A Biomedical Solutions Ltd. (TASE:DNA) announced a private placement of 15,277,778 common shares at a price of ILS 0.36 per share for gross proceeds of ILS 5,500,000 on August 2, 2017. The transaction will include participation from 11 investors of which eight are third parties institutional, corporate and private investors and three who are directors or officers - Zeev Bronfeld , Yonatan Malka, Chief Executive Officer of the company and Tony Klein, Chief Financial Officer of the company. Zeev Bronfeld will invest ILS 400,000 and Jonathan Malka will invest ILS 600,000 in the transaction. The company will also issue warrants convertible into shares of a company to third parties. Each warrant can be exercised at ILS 0.5 and will be available for a period of 3 years since date of allocation. The company will issue at a price of ILS 0.36 per share and for every three shares purchased by the investor will get an extra warrant. The securities issued are subject to a hold period of six months. The total number of the shares and the shares deriving from the exercise of warrants, assuming full exercise of all the option warrants shall constitute about 12.5% of the issued and paid-up share capital of the company after the allocation, about 12.2% fully diluted. The transaction has been approved by audit committee and the board of directors of the company. The transaction is subject to the approval of the general meeting.